BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 17224894)

  • 1. The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs.
    Vakil N
    Rev Gastroenterol Disord; 2006; 6(4):221-6. PubMed ID: 17224894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of anti-ulcerative drugs in treatment and prevention of gastropathies induced by nonsteroidal anti-inflammatory drugs].
    Fialová P; Vlcek J
    Vnitr Lek; 2004 Nov; 50(11):858-66. PubMed ID: 15648967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis.
    Fries JF; Murtagh KN; Bennett M; Zatarain E; Lingala B; Bruce B
    Arthritis Rheum; 2004 Aug; 50(8):2433-40. PubMed ID: 15334455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness.
    Targownik LE; Thomson PA
    Can Fam Physician; 2006 Sep; 52(9):1100-5. PubMed ID: 17279220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
    Goldstein JL; Larson LR; Yamashita BD
    Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
    Lanas A; García-Rodríguez LA; Arroyo MT; Bujanda L; Gomollón F; Forné M; Aleman S; Nicolas D; Feu F; González-Pérez A; Borda A; Castro M; Poveda MJ; Arenas J;
    Am J Gastroenterol; 2007 Mar; 102(3):507-15. PubMed ID: 17338735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Steen KS; Lems WF; Dijkmans BA
    Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1649-52. PubMed ID: 10494299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention.
    Scheiman JM
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():39-49. PubMed ID: 16369226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.